BiotechTube

Itolizumab [Bmab 600]

Phase 1Completed
1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Lupus Erythematosus

Conditions

Lupus Erythematosus, Lupus Nephritis

Trial Timeline

Oct 1, 2019 → Jan 18, 2024

NCT ID
NCT04128579

About Itolizumab [Bmab 600]

Itolizumab [Bmab 600] is a phase 1 stage product being developed by Biocon for Lupus Erythematosus. The current trial status is completed. This product is registered under clinical trial identifier NCT04128579. Target conditions include Lupus Erythematosus, Lupus Nephritis.

What happened to similar drugs?

8 of 20 similar drugs in Lupus Erythematosus were approved

Approved (8) Terminated (7) Active (7)
✅tacrolimusAstellas PharmaApproved
✅Rosuvastatin + SimvastatinAstraZenecaApproved
✅AnifrolumabAstraZenecaApproved
✅BMS-986165Bristol Myers SquibbApproved
✅versus hydroxychloroquineSanofiApproved
✅Belimumab plus Early Vaccination + Belimumab plus Late VaccinationGSK plcApproved
✅Placebo plus standard therapy + Belimumab 10 mg/kg plus standard therapy + Standard therapyGSK plcApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04128579Phase 1Completed

Competing Products

20 competing products in Lupus Erythematosus

See all competitors
ProductCompanyStageHype Score
Tabalumab Auto-Injector + Tabalumab Prefilled SyringeEli LillyPhase 3
32
Baricitinib + PlaceboEli LillyPhase 2
35
DS-7011a + PlaceboDaiichi SankyoPhase 1
29
DS-7011a + PlaceboDaiichi SankyoPhase 1/2
32
tacrolimusAstellas PharmaPhase 3
40
TacrolimusAstellas PharmaPre-clinical
26
tacrolimus capsule + tacrolimus placebo + leflunomide tablet + leflunomide placebo + prednisoneAstellas PharmaPhase 3
32
tacrolimusAstellas PharmaApproved
35
Tacrolimus capsules + Cyclophosphamide injections + PrednisoneAstellas PharmaPhase 3
40
E6742EisaiPhase 1/2
32
Baricitinib + PlaceboEli LillyPhase 3
40
Baricitinib + PlaceboEli LillyPhase 3
32
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of CareEli LillyPhase 3
40
LY3361237 + PlaceboEli LillyPhase 2
27
LY2127399 + PlaceboEli LillyPhase 3
32
LY3361237 + PlaceboEli LillyPhase 1
29
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeksEli LillyPhase 3
40
Baricitinib + PlaceboEli LillyPhase 3
32
LY3471851 + PlaceboEli LillyPhase 1
29
LY3471851 + PlaceboEli LillyPhase 2
35